ELVN

Enliven Therapeutics Inc

49.43

Nov 06 • 3:59 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Nov 05, 6:15 PMEnliven Therapeutics beats Q3 2026 EPS and revenue estimates, secures FDA alignment on ENABLE-2 Phase 3 trial in CML

Peers: AAPG ERAS TYRA IDYA RLAY KURA SNDX NVS BDTX TAK

| Held by: VTI IWM VXF IWO IBB DFAS VTWO SCHA IHE XPH

Scroll to Statements

Index	RUT
Market Cap	3.64B
Enterprise Value	2.75B
Income	-113.48M
Sales	0.00M
Book/sh	11.92
Cash/sh	12.02
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	60
IPO	Mar 12, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.15
P/C	4.11
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	45.95
Current Ratio	45.95
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.70
EPS next Y	-2.09
EPS next Q	-0.46
EPS this Y	6.19%
EPS next Y	-21.81%
EPS next 5Y	-13.28%
EPS past 3/5Y	46.65% 33.56%
Sales past 3/5Y	- -
EPS Y/Y TTM	7.94%
Sales Y/Y TTM	-
EPS Q/Q	-9.46%
Sales Q/Q	-
Earnings	Nov 05 AMC
EPS/Sales Surpr.	19.62% -

Insider Own	16.82%
Insider Trans	-10.12%
Inst Own	99.30%
Inst Trans	39.83%
ROA	-16.35%
ROE	-16.77%
ROIC	-12.93%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	16.07%
SMA50	4.60%
SMA200	14.36%
Trades

Shs Outstand	73.56M
Shs Float	61.22M
Short Float	15.24%
Short Ratio	7.00
Short Interest	9.33M
52W High	62.32 -20.68%
52W Low	14.78 234.33%
Volatility	6.52% 4.77%
ATR (14)	2.22
RSI (14)	63.72
Beta	0.30
Rel Volume	0.00
Avg Volume	1.33M
Volume	0

Perf Week	11.71%
Perf Month	21.66%
Perf Quarter	-16.81%
Perf Half Y	21.30%
Perf YTD	220.97%
Perf Year	170.11%
Perf 3Y	301.87%
Perf 5Y	223.49%
Perf 10Y	-
Recom	1.13
Target Price	73.85
Prev Close	49.43
Price	49.43
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$73.85

Implied Upside

+49.4%

Analysts12incl. previous ratings

Rating Distribution12 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 02, 2026	Initiated	MMorgan Stanley	Overweight	$70	+41.6%
Oct 01, 2026	Initiated	JJP Morgan	Overweight	$75	+51.7%
Aug 18, 2026	Initiated	WWilliam Blair	Outperform
Aug 18, 2026	Initiated	BBarclays	Overweight	$78	+57.8%
Jun 09, 2026	Initiated	SStifel	Buy	$60	+21.4%
May 12, 2026	Initiated	GGuggenheim	Buy	$80	+61.8%
Jun 16, 2025	Initiated	GGoldman	Buy	$37	-25.1%
Dec 13, 2024	Initiated	BBTIG Research	Buy	$42	-15.0%
Sep 09, 2024	Initiated	HH.C. Wainwright	Buy	$37	-25.1%
Jun 11, 2024	Initiated	RRobert W. Baird	Outperform	$32	-35.3%
Apr 09, 2024	Initiated	MMizuho	Buy	$34	-31.2%
Mar 29, 2023	Initiated	JJefferies	Buy	$27	-45.4%

Nov-05-26 04:05PM	Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update (PR Newswire) -5.21% +10.36%
Oct-14-26 04:30PM	Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year (PR Newswire)
Oct-07-26 11:21AM	Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial (BioPharma Dive)
Oct-06-26 04:05PM	Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia (PR Newswire) -6.77%
Sep-03-26 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
06:05PM	Loading…
Aug-31-26 06:05PM	Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting (PR Newswire)
Aug-05-26 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (PR Newswire)
Jul-10-26 07:26PM	HMI Capital Pares Its Stake in AI Company nCino (Barrons.com)
Jun-15-26 04:40PM	Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) -8.17%
Jun-12-26 02:22PM	ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development (Stocktwits) +14.30%
Jun-11-26 10:39PM	Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +9.08%
04:05PM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
10:36AM	Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN) (InvestorsHub)
08:00AM	Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components (PR Newswire)
Jun-09-26 09:32AM	Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls (The Fly) +7.37%
04:05PM	Loading…
Jun-03-26 04:05PM	Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress (PR Newswire)
May-21-26 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-12-26 09:53AM	Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML (PR Newswire) +6.85%
May-07-26 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire)
Feb-25-26 04:05PM	Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference (PR Newswire)
Jan-08-26 02:16PM	Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars (Benzinga) +50.29%
09:00AM	Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones (PR Newswire)
Jan-07-26 09:00AM	Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development (PR Newswire)
Dec-11-25 04:21PM	Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules (PR Newswire) -6.94% -10.18%
09:00AM	Enliven Therapeutics Announces New CEO to Drive Next Phase of Development (PR Newswire)
Dec-03-25 09:55AM	Wall Street Analysts Believe Enliven Therapeutics, Inc. (ELVN) Could Rally 101.26%: Here's is How to Trade (Zacks)
Nov-17-25 09:55AM	Does Enliven Therapeutics, Inc. (ELVN) Have the Potential to Rally 87.49% as Wall Street Analysts Expect? (Zacks)
Nov-12-25 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire)
Sep-12-25 09:55AM	Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know (Zacks)
Sep-09-25 12:00PM	Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know (Zacks)
09:55AM	Loading…
Aug-27-25 09:55AM	How Much Upside is Left in Enliven Therapeutics, Inc. (ELVN)? Wall Street Analysts Think 102.41% (Zacks)
Aug-25-25 06:20PM	Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting (PR Newswire)
Aug-13-25 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (PR Newswire) +5.80%
Jul-18-25 09:55AM	Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? (Zacks)
Jun-17-25 01:33PM	Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data (Insider Monkey) -5.59%
Jun-16-25 04:05PM	Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire) +5.39%
Jun-13-25 09:30AM	Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +11.44%
06:10AM	Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
06:02AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress (PR Newswire)
May-22-25 04:05PM	Enliven Therapeutics to Present at Upcoming Investor Conferences (PR Newswire)
May-17-25 12:40PM	Enliven price target lowered to $27 from $36 at JonesResearch (TipRanks)
May-14-25 04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (PR Newswire) -10.41%
09:56AM	Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress (PR Newswire)
Apr-22-25 02:54PM	Enliven Therapeutics: Awaiting Additional Trial Data (Seeking Alpha) +10.79%
Apr-02-25 04:03PM	Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting (PR Newswire) +5.19%
Mar-13-25 04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (PR Newswire)
Feb-25-25 04:05PM	Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference (PR Newswire) -5.71%
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Nov-13-24 04:05PM	Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update (PR Newswire) -5.04%
Nov-07-24 04:05PM	Enliven Therapeutics to Present at the Jefferies London Healthcare Conference (PR Newswire)
Oct-18-24 04:38PM	Why this largely unknown company is one analyst's top biotech pick (Yahoo Finance Video)
Oct-04-24 09:00AM	FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket (PR Newswire) +7.92%
Sep-30-24 04:52AM	Enliven Therapeutics ELVN-001 shows promise in Phase I CML trial (Clinical Trials Arena) +5.84%
Sep-28-24 09:35AM	Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Sep-26-24 08:50AM	Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going (Zacks)
Sep-18-24 04:05PM	Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML (GlobeNewswire) +6.02%
Sep-09-24 02:05PM	Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst (Benzinga) +7.28%
Sep-04-24 09:55AM	Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? (Zacks)
Aug-16-24 09:55AM	Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet (Zacks)
Aug-13-24 04:05PM	Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update (GlobeNewswire)
May-29-24 04:05PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) -8.14% +5.67%
May-20-24 05:06PM	Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing (MT Newswires)
May-14-24 10:54PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 (InvestorPlace)
05:01PM	Enliven Therapeutics Q1 Loss Narrows (MT Newswires)
04:05PM	Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update (GlobeNewswire)
Apr-19-24 03:03PM	MasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors (Barrons.com)
Apr-11-24 03:44PM	Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program (Benzinga) +20.18%
07:55AM	Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia (GlobeNewswire)
Apr-09-24 04:05PM	Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors (GlobeNewswire)
Mar-28-24 04:05PM	Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 (GlobeNewswire) -5.58% +7.45%
Mar-23-24 01:51AM	Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares (GuruFocus.com)
Mar-19-24 08:30AM	Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates (GlobeNewswire) +38.77%
Mar-14-24 09:53PM	ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -5.95%
04:05PM	Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-27-24 04:05PM	Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Jan-03-24 09:01AM	Enliven Therapeutics Inc CFO Benjamin Hohl Sells 11,870 Shares (GuruFocus.com)
Nov-09-23 04:05PM	Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -7.97%
Aug-17-23 06:40AM	7 A-Rated Biotech Stocks for Your August Buy List (InvestorPlace) +6.00%
Aug-10-23 04:05PM	Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-31-23 04:55PM	Enliven Therapeutics to Present at Two Upcoming Investor Conferences (GlobeNewswire) +8.85%
May-11-23 04:05PM	Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Mar-24-23 06:30AM	7 Biotech Stocks Sitting in the Sweet Spot (InvestorPlace)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kunkel Lori Anne	Director	Oct 30 '26	Option Exercise	12.48	11,041	137,780	52,925	Nov 03 05:21 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 19 '26	Option Exercise	14.85	6,018	89,367	44,018	Oct 21 05:53 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Oct 19 '26	Sale	38.48	6,018	231,546	38,000	Oct 21 05:53 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 19 '26	Option Exercise	2.48	5,000	12,400	30,000	Oct 21 05:51 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Oct 19 '26	Sale	38.47	5,000	192,342	25,000	Oct 21 05:51 PM
Collins Helen Louise	Director	Oct 19 '26	Proposed Sale	37.32	15,000	559,800		Oct 19 04:16 PM
Garland J. Scott	Director	Oct 01 '26	Option Exercise	15.47	13,000	201,110	13,000	Oct 05 04:57 PM
Garland J. Scott	Director	Oct 01 '26	Sale	46.67	13,000	606,719	0	Oct 05 04:57 PM
JEFFREY GARLAND	Director	Oct 01 '26	Proposed Sale	46.67	13,000	606,719		Oct 01 04:02 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 17 '26	Option Exercise	14.85	3,982	59,133	44,018	Sep 21 05:23 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Sep 17 '26	Sale	50.35	6,018	303,003	38,000	Sep 21 05:23 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Sep 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Sep 21 05:22 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Sep 17 '26	Sale	50.35	5,000	251,754	25,000	Sep 21 05:22 PM
Hohl Benjamin	Officer	Sep 17 '26	Proposed Sale	49.12	12,036	591,208		Sep 17 04:33 PM
Heyman Richard A.	resigned from BOD	Sep 04 '26	Proposed Sale	59.28	38,000	2,252,830		Sep 04 02:58 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Aug 17 '26	Sale	58.58	6,018	352,551	40,036	Aug 19 04:17 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Aug 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Aug 19 04:16 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Aug 17 '26	Sale	58.59	5,000	292,931	25,000	Aug 19 04:16 PM
Derynck Mika K	Director	Aug 04 '26	Option Exercise	10.84	158,795	1,720,967	158,795	Aug 06 08:18 PM
Derynck Mika K	Director	Aug 04 '26	Sale	60.21	158,795	9,561,587	0	Aug 06 08:18 PM
Derynck Mika K	Director	Aug 04 '26	Proposed Sale	58.04	158,795	9,216,462		Aug 04 04:39 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 17 '26	Option Exercise	2.48	1,072	2,659	52,072	Jul 21 05:24 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jul 17 '26	Sale	52.64	6,018	316,780	46,054	Jul 21 05:24 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jul 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Jul 21 05:23 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jul 17 '26	Sale	52.67	5,000	263,373	25,000	Jul 21 05:23 PM
Collins Helen Louise	Officer	Jul 17 '26	Proposed Sale	50.86	15,000	762,900		Jul 17 04:36 PM
Kunkel Lori Anne	Director	Jul 06 '26	Sale	50.49	10,000	504,903	41,884	Jul 08 05:15 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 22 '26	Sale	45.36	860,123	39,014,046	219,405	Jun 24 07:19 PM
OrbiMed Genesis Master Fund, L	Shareholder	Jun 22 '26	Proposed Sale	45.96	24,846	1,141,922		Jun 22 08:13 PM
OrbiMed Private Investments VI	Shareholder	Jun 22 '26	Proposed Sale	45.96	787,024	36,171,623		Jun 22 08:10 PM
The Biotech Growth Trust PLC	Shareholder	Jun 22 '26	Proposed Sale	45.96	29,385	1,350,535		Jun 22 08:08 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 17 '26	Option Exercise	2.48	6,018	14,925	57,018	Jun 22 05:13 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Jun 17 '26	Sale	43.80	6,018	263,577	51,000	Jun 22 05:13 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jun 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Jun 22 05:11 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Jun 17 '26	Sale	43.80	5,000	219,017	25,000	Jun 22 05:11 PM
ORBIMED ADVISORS LLC	10% Owner	Jun 15 '26	Sale	45.02	281,408	12,668,988	245,728	Jun 17 07:45 PM
Hohl Benjamin	Officer	Jun 17 '26	Proposed Sale	42.55	18,054	768,198		Jun 17 04:24 PM
The Biotech Growth Trust PLC	Shareholder	Jun 15 '26	Proposed Sale	42.36	10,243	433,893		Jun 15 09:23 PM
OrbiMed Private Investments VI	Shareholder	Jun 15 '26	Proposed Sale	42.36	272,322	11,535,560		Jun 15 09:21 PM
OrbiMed Genesis Master Fund, L	Shareholder	Jun 15 '26	Proposed Sale	42.36	9,086	384,883		Jun 15 09:18 PM
Kunkel Lori Anne	Director	Jun 05 '26	Sale	34.54	10,000	345,351	51,884	Jun 09 04:49 PM
Kunkel Lori Anne	Board Member	Jun 05 '26	Proposed Sale	35.49	20,000	709,800		Jun 05 04:29 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	May 18 '26	Option Exercise	2.48	5,000	12,400	30,000	May 20 04:18 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	May 18 '26	Sale	39.79	5,000	198,971	25,000	May 20 04:18 PM
Collins Helen Louise	Officer	May 18 '26	Proposed Sale	41.34	15,000	620,100		May 18 04:28 PM
Lyssikatos Joseph P	Officer	Apr 30 '26	Proposed Sale	42.40	25,000	1,060,000		Apr 30 04:17 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Apr 21 08:40 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Apr 17 '26	Sale	47.67	5,000	238,352	25,000	Apr 21 08:40 PM
Lyssikatos Joseph P	Officer	Mar 31 '26	Proposed Sale	36.59	25,000	914,750		Mar 31 04:29 PM
ANDREW PHILLIPS	Former Director	Mar 31 '26	Proposed Sale	38.55	26,035	1,003,610		Mar 31 04:26 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 25 '26	Option Exercise	2.48	40,000	99,200	65,000	Mar 27 04:57 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 25 '26	Sale	35.10	40,000	1,404,024	25,000	Mar 27 04:57 PM
Collins Helen Louise	Officer	Mar 25 '26	Proposed Sale	31.15	45,000	1,401,750		Mar 25 04:29 PM
Patel Anish	Officer	Mar 24 '26	Proposed Sale	30.81	100,000	3,081,000		Mar 24 04:26 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 17 '26	Option Exercise	2.48	5,000	12,400	30,000	Mar 19 05:50 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 17 '26	Sale	27.76	5,000	138,800	25,000	Mar 19 05:50 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 09 '26	Option Exercise	2.48	29,871	74,080	54,871	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 10 '26	Option Exercise	2.48	10,129	25,120	35,129	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 09 '26	Sale	30.02	29,871	896,811	25,000	Mar 11 05:32 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Mar 10 '26	Sale	30.19	10,129	305,827	25,000	Mar 11 05:32 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Mar 06 '26	Sale	29.58	10,000	295,839	51,000	Mar 10 06:15 PM
Collins Helen Louise	Officer	Mar 09 '26	Proposed Sale	29.44	45,000	1,324,800		Mar 09 04:12 PM
Hohl Benjamin	Officer	Mar 06 '26	Proposed Sale	29.29	10,000	292,900		Mar 06 04:06 PM
Heyman Richard A.	Director	Feb 17 '26	Sale	26.18	1,230	32,196	22,647	Feb 19 06:38 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Feb 17 '26	Option Exercise	2.48	45,000	111,600	70,000	Feb 19 06:36 PM
Collins Helen Louise	CHIEF MEDICAL OFFICER	Feb 17 '26	Sale	26.17	45,000	1,177,862	25,000	Feb 19 06:36 PM
Lyssikatos Joseph P	Officer	Feb 18 '26	Proposed Sale	26.13	75,000	1,959,750		Feb 18 04:25 PM
Kintz Samuel	Officer	Feb 17 '26	Proposed Sale	26.72	75,000	2,004,000		Feb 17 04:50 PM
Heyman Richard A.	Director	Feb 17 '26	Proposed Sale	26.72	1,230	32,866		Feb 17 04:44 PM
Collins Helen Louise	Officer	Feb 17 '26	Proposed Sale	26.72	45,000	1,202,400		Feb 17 04:40 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Feb 06 '26	Sale	29.04	5,000	145,219	740,188	Feb 10 06:12 PM
ANDREW PHILLIPS	Former Director	Feb 02 '26	Proposed Sale	28.00	21,844	611,719		Feb 02 05:38 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 20 '26	Sale	26.75	20,000	535,099	745,188	Jan 22 05:34 PM
Heyman Richard A.	Director	Jan 20 '26	Sale	26.75	1,230	32,902	23,877	Jan 22 05:33 PM
Heyman Richard A.	Director	Jan 20 '26	Proposed Sale	26.71	1,230	32,853		Jan 20 04:55 PM
Patel Anish	CHIEF OPERATING OFFICER	Jan 09 '26	Sale	27.99	48,300	1,351,762	215,011	Jan 13 05:54 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 09 '26	Sale	27.22	91,198	2,482,578	765,188	Jan 12 05:12 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Jan 08 '26	Sale	24.05	41,302	993,436	856,386	Jan 12 05:12 PM
Heyman Richard A.	Director	Jan 08 '26	Sale	25.03	9,635	241,156	25,545	Jan 12 05:11 PM
Heyman Richard A.	Director	Jan 09 '26	Sale	25.00	4,285	107,125	25,107	Jan 12 05:11 PM
Lyssikatos Joseph P	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:50 PM
Kintz Samuel	Officer	Jan 09 '26	Proposed Sale	23.25	75,000	1,743,750		Jan 09 04:49 PM
Patel Anish	Officer	Jan 09 '26	Proposed Sale	23.25	48,300	1,122,975		Jan 09 04:18 PM
Kintz Samuel	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:42 PM
Lyssikatos Joseph P	Officer	Jan 08 '26	Proposed Sale	15.47	82,500	1,276,275		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	1,620	25,061		Jan 08 04:26 PM
Heyman Richard A.	Director	Jan 08 '26	Proposed Sale	15.47	12,300	190,281		Jan 08 04:18 PM
Hohl Benjamin	CHIEF FINANCIAL OFFICER	Dec 22 '25	Option Exercise	2.48	13,000	32,240	36,000	Dec 23 06:47 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Dec 19 '25	Sale	16.84	5,000	84,206	897,688	Dec 23 06:45 PM
Kunkel Lori Anne	Director	Dec 17 '25	Option Exercise	1.12	15,958	17,873	30,712	Dec 19 05:58 PM
Lyssikatos Joseph P	Officer	Dec 19 '25	Proposed Sale	16.68	5,000	83,400		Dec 19 04:32 PM
Kintz Samuel	Officer	Dec 17 '25	Proposed Sale	16.91	5,000	84,550		Dec 17 04:23 PM
Patel Anish	CHIEF OPERATING OFFICER	Dec 08 '25	Sale	21.02	6,663	140,073	263,311	Dec 10 05:13 PM
Patel Anish	Officer	Dec 08 '25	Proposed Sale	21.81	6,663	145,320		Dec 08 04:18 PM
Lyssikatos Joseph P	CHIEF SCIENTIFIC OFFICER	Nov 19 '25	Sale	22.33	12,500	279,155	902,688	Nov 21 05:28 PM
Kintz Samuel	PRESIDENT AND CEO	Nov 17 '25	Sale	21.82	12,500	272,739	890,392	Nov 19 06:45 PM
Lyssikatos Joseph P	Officer	Nov 19 '25	Proposed Sale	22.59	12,500	282,375		Nov 19 04:05 PM
Kintz Samuel	Officer	Nov 17 '25	Proposed Sale	22.07	12,500	275,875		Nov 17 04:16 PM

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

CEOMr. Richard A. Fair M.B.A.

Co-Founder & Head of PipelineMr. Samuel S. Kintz M.B.A.

CFO & Head of Corporate DevelopmentMr. Benjamin Hohl

Chief Medical OfficerDr. Helen Louise Collins M.D.

Co-Founder & Research FellowDr. Joseph P. Lyssikatos Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ELVN

Enliven Therapeutics Inc

Upgrade your Finviz experience